In December of 2007, Illumigen Biosciences Inc was acquired by Cubist Pharmaceuticals, Inc. (another SBIR company). Illumigen Biosciences, Inc. is the market leader in the use of proprietary genetic technologies to identify naturally occurring health-inducing mutations. These beneficial mutations provide a rapid method for developing novel drugs with improved efficacy and fewer side effects. Illumigen is using its technologies to develop drugs to treat hepatitis C infection, obesity, and other diseases
